Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

DL, White; VA, Saunders; P, Dang; J, Engler; A, Venables; S, Zrim; A, Zannettino; K, Lynch; PW, Manley; T, Hughes

doi:10.1182/blood-2007-06-093617

Public

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

Shared by NobleBlocks on Aug 30, 2007 • 12:00 AM UTC

Authors:

White DL

Saunders VA

Dang P

Abstract

Interpatient variability in intracellular uptake and retention (IUR) of imatinib may be due to variable function of the OCT-1 influx pump. OCT-1 activity was measured in pretherapy blood from chronic myeloid leukemia (CML) patients by calculating the difference in IUR of [(14)C]-imatinib with and wi...

Discussions